If you made any changes in Pure these will be visible here soon.

Personal profile


Andrew Powell is the Operations Manager for the Centre for Drug Candidate Optimisation (CDCO). Andrew has over 15 years' experience working within the academic and biotechnology sectors in scientific and management roles. He completed an undergraduate degree in Biomedical Science and Ph.D. in Physiology at Monash University. In 2003, he accepted a post-doctoral role with the newly established CDCO and worked across the Biopharmaceutics section, before moving on to lead the Metabolism Team. After five years with the Centre, Andrew took up a position as Preclinical Project Manager with biotechnology company Cytopia. In this role, he managed a formal IND-enabling toxicology program and associated regulatory submissions, as well as various CMC, pharmacokinetic and efficacy studies. In 2010, Andrew returned to the CDCO in his current role where he manages operations to ensure that the working needs of collaborators and key stakeholders are met. He also liaises with potential external partners to plan and establish new collaborative projects and acts as a project coordinator for selected projects. 

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2019 2021

Research Output 2001 2017

Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent

Ogunniyi, A. D., Khazandi, M., Stevens, A. J., Sims, S. K., Page, S. W., Garg, S., Venter, H., Powell, A., White, K., Petrovski, K. R., Laven-Law, G., Tótoli, E. G., Salgado, H. R., Pi, H., Coombs, G. W., Shinabarger, D. L., Turnidge, J. D., Paton, J. C., McCluskey, A. & Trott, D. J., 1 Sep 2017, In : PLoS ONE. 12, 9, 23 p., e0183457.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)

Zheng, Z., Pinson, J. A., Mountford, S. J., Orive, S., Schoenwaelder, S. M., Shackleford, D., Powell, A., Nelson, E. M., Hamilton, J. R., Jackson, S., Jennings, I. G. & Thompson, P. E., 21 Oct 2016, In : European Journal of Medicinal Chemistry. 122, p. 339-351 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Drinkwater, N., Vinh, N. B., Mistry, S. N., Bamert, R. S., Ruggeri, C., Holleran, J. P., Loganathan, S., Paiardini, A., Charman, S. A., Powell, A. K., Avery, V. M., McGowan, S. & Scammells, P. J., 3 Mar 2016, In : European Journal of Medicinal Chemistry. 110, p. 43-64 22 p.

Research output: Contribution to journalArticleResearchpeer-review

Simplified silvestrol analogues with potent cytotoxic activity

Hawkins, B. C., Lindqvist, L. M., Nhu, D. Q., Sharp, P. P., Segal, D., Powell, A. K., Campbell, M., Ryan, E., Chambers, J. M., White, J., Rizzacasa, M. A., Lessene, G., Huang, D. CS. & Burns, C. J., 2014, In : ChemMedChem. 9, 7, p. 1556 - 1566 11 p.

Research output: Contribution to journalArticleResearchpeer-review

3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): An orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy

Williams, S. J., Zammit, S. C., Cox, A. J., Shackleford, D., Morizzi, J., Zhang, Y., Powell, A. K., Gilbert, R. E., Krum, H. & Kelly, D. J., 2013, In : Bioorganic and Medicinal Chemistry Letters. 23, 24, p. 6868 - 6873 6 p.

Research output: Contribution to journalArticleResearchpeer-review